Search
for
Sort by
Research 391–420 of 1000+
- Immunological characteristics and histological distribution of human hair fibrous proteins studied with anti-hair keratin monoclonal antibodies HKN-2, HKN-4, and HKN-6.
- Acquired Localized Longitudinal Pachyonychia and Onychomatrical Tumors: A Comparative Study to Onychomatricomas (5 Cases) and Onychocytic Matricomas (4 Cases)
- Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
- Relationship between working hours and probability to take alopecia medicine among Korean male workers: a 4-year follow-up study
- Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol
- Synthesis, Crystal Structure and Supramolecular Features of Novel 2,4-Diaminopyrimidine Salts
- Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase
- Essential Fatty Acid Deficiency (EFAD) in a Patient with Vascular Ehlers Danlos Syndrome (EDS-4) (P12-053-19)
- 75202 Evaluation of the anti-dandruff and soothing effect of a hair conditioner containing 0.4% piroctone olamine and niacinamide
- Trends in dermatological presentations at the emergency department of a tertiary hospital in Singapore: a 4-year analysis pre- and during COVID-19
- LB1034 Meta-analysis of scalp transcriptome defines alopecia areata subtypes and molecular response to four (4) treatments with jak inhibiting properties
- Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
- 43046 Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
- 877 Loss of UBE2N in keratinocytes leads to skin inflammation and immune infiltration through IRAK1/4-mediated processes
- Book Review: “Integrated Procedures in Facial Cosmetic Surgery” ISBN 978-3-030-46992-4 ISBN 978-3-030-46993-1 (eBook) © Springer Nature Switzerland AG 2021
- <strong>Ultrasound-Assisted Facile Synthesis and Anticancer Evaluation of Novel N-(2-substituted phenyl-4-oxathiazolidine-3-carbonothioyl) benzamide</strong>
- 310 Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with 4.5% Nasal Testosterone Gel (Natesto)
- 1P-230: Synthesis and in vitro characterization of 68 Ga labeled Fe 3 O 4 nanoparticles for drug delivery
- 1262 ONE YEAR FINASTERIDE THERAPY IN MEN WITH A SERUM PSA GREATER THAN 4 NG/ML WHO HAD UNDERGONE REPEAT BIOPSY
- 115 AE法による実機水車発電機軸受の診断(セッション4 評価・診断II)
- Changes in hair growth characteristics in response to an increase in dietary zinc up to 4.5 times maintenance from three different commercially available sources in the dog
- 1340 低熱セメントを用いた高強度コンクリート実大施工実験 : その4 硬化コンクリートの性状
- Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): Three- and 4-year results
- The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
- The Long-Term Effect Of Specific Type II 5α-Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial
- Menopause, skin and common dermatoses. Part 4: oral disorders
- Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968)
- Chronicles of A.I. Pospelov Moscow Society of Dermatovenereologists and Cosmetologists (MSDC was founded on October 4, 1891) Bulletin of the MSDС № 1167
- BindingDB Entry 50021519: Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment.
- Número Actual: Vol. 2 Núm. 4 (2021) Pág. 1-67